July 14, 2025 09:39 PM EDT

FDA employees let go in April receive final termination notices

Zachary Brennan

Senior Editor

As many as 3,500 FDA employees received an email Monday evening informing them that they have been officially fired, an HHS spokesperson confirmed to …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

TRENDING NOW

FDA employees let go in April receive final termination notices

Zachary Brennan

Senior Editor

Sign up to read this article for free.

FDA chief calls for lower user fees as negotiations begin for eighth round of PDUFA

AstraZeneca posts a pivotal trial win for blood pressure pill behind $1.3B deal

After long saga, 23andMe's deal with Anne Wojcicki's nonprofit finally closes

FDA declines to approve Ultragenyx's Sanfilippo gene therapy, citing manufacturing issues

Boehringer, LEO ink deal for IL-36 drug; Bayer’s Kerendia gets another indication

Merck sends new monthly oral PrEP to Phase 3 after earlier islatravir setback

FDA em­ploy­ees let go in April re­ceive fi­nal ter­mi­na­tion no­tices

Zachary Brennan

Senior Editor

Sign up to read this article for free.

more like this

FDA chief calls for low­er user fees as ne­go­ti­a­tions be­gin for eighth round of PDU­FA

As­traZeneca posts a piv­otal tri­al win for blood pres­sure pill be­hind $1.3B deal

Af­ter long saga, 23and­Me's deal with Anne Wo­j­ci­ck­i's non­prof­it fi­nal­ly clos­es

FDA de­clines to ap­prove Ul­tragenyx's San­fil­ip­po gene ther­a­py, cit­ing man­u­fac­tur­ing is­sues

Boehringer, LEO ink deal for IL-36 drug; Bay­er’s Keren­dia gets an­oth­er in­di­ca­tion

Mer­ck sends new month­ly oral PrEP to Phase 3 af­ter ear­li­er is­la­travir set­back

FDA employees let go in April receive final termination notices

FDA chief calls for lower user fees as negotiations begin for eighth round of PDUFA

AstraZeneca posts a pivotal trial win for blood pressure pill behind $1.3B deal

After long saga, 23andMe's deal with Anne Wojcicki's nonprofit finally closes

FDA declines to approve Ultragenyx's Sanfilippo gene therapy, citing manufacturing issues

Boehringer, LEO ink deal for IL-36 drug; Bayer’s Kerendia gets another indication

Merck sends new monthly oral PrEP to Phase 3 after earlier islatravir setback